ClustALL: A robust clustering strategy for stratification of patients with acutely 1 2 decompensated cirrhosis 3 4 Sara Palomino-Echeverria, spalomie@navarra.es, Spain¹ 5 Estefania Huergo, ehuergoi@navarra.es, Spain¹ 6 7 Asier Ortega-Legarreta, aortegal@navarra.es, Spain¹ Eva M. Uson, eva.uson@efclif.com, Spain² 8 Ferran Aguilar, ferran.aguilar@efclif.com, Spain² 9 Carlos de la Pena, carlos.delapena@efclif.com, Spain² 10 Cristina Lopez-Vicario, clopezv@recerca.clinic.cat, Spain³ 11 Carlo Alessandria, carloalessandria@libero.it, Italy Wim Laleman, wim.laleman@uzleuven.be, Belgium⁵ 12 13 Alberto Farias Queiroz, alberto.farias@fm.usp.br, Brazil⁶ 14 Richard Moreau, richard.moreau@inserm.fr, France^{2,7,8,9} 15 Javier Fernandez, javier.fernandez@efclif.com, Spain² 16 Vicente Arroyo, vicente.arroyo@efclif.com, Spain² 17 Paolo Caraceni, paolo.caraceni@unibo.it, Italy Vincenzo Lagani, vincenzo.lagani@gmail.com, Georgia^{11,12,13} 18 19 Cristina Sanchez, cristina.sanchez@efclif.com, Spain 20 Joan Claria, jclaria@clinic.cat, Spain³ 21 Jesper Tegner, jesper.tegner@kaust.edu.sa, Saudi Arabia¹¹ $\overline{22}$ Jonel Trebicka, jonel.trebicka@ukmuenster.de, Germany^{2,14} $\overline{23}$ Narsis Kiani, narsis.kiani@ki.se, Sweden¹⁵ $\overline{24}$ Nuria Planell, nplanellpic@unav.es, Spain^{1, 16*} 25 Pierre-Emmanuel Rautou, pierre-emmanuel.rautou@inserm.fr, France^{7,17*} 26 David Gomez-Cabrero, david.gomez.cabrero@navarra.es, Spain^{1,11} 27 28 PREDICT investigators, ACLARA investigators, DECISION investigators. 29 30 Affiliations: 31 1: Unit of Translational Bioinformatics, Navarrabiomed - Fundación Miguel Servet, Pamplona, Spain 32 2: European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain 33 34 3: Biochemistry and Molecular Genetics Service, Hospital Clínic-IDIBAPS, Barcelona, Spain; European Foundation for the Study of Chronic Liver Failure (EF Clif) and Grifols Chair, Barcelona, Spain; CIBERehd, Barcelona, Spain; Department of 35 36 Biomedical Sciences, University of Barcelona, Barcelona, Spain 4: A.O.U. Città della Salute e della Scienza Torino, Torino, Italy

- 37 5: University of Leuven, Leuven, Belgium
- 38 6: Department of Gastroenterology, Hospital das Clínicas, University of São Paulo School of Medicine, Brazil
- 39 7: Université Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR, Paris, France.
- 40 8: Assistance Publique-Hôpitaux de Paris (AP-HP), France
- 41 9: Hôpital Beaujon, Service d'Hépatologie, Clichy, France
- 42 10: University of Bologna, Department of Medical and Surgical Science, Bologna, Italy
- 43 11: Biological and Environmental Science and Engineering Division, King Abdullah University of Science and Technology
- 44 (KAUST), Thu wal, Sau di Arabia.
- 45 12: SDAIA-KAUST Center of Excellence in Data Science and Artificial Intelligence, Thuwal, Saudi Arabia
- 46 13: Institute of Chemical Biology, Ilia State University, Tbilisi 0162, Georgia
- 47 14: Department of internal medicine B, University of Münster, Münster, Germany
- 48 15: Algorithmic Dynamics lab, Karolinska Institutet, Solna, Sweden
- 49 16: Universidad de Navarra, CIMA, Computational Biology Program, Instituto de Investigación Sanitaria de Navarra
 50 (IdiSNA), 31008 Navarra, Spain.
- 51 17: Service d'Hépatologie, AP-HP, Hôpital Beaujon, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie,
- 52 FILFOIE, ERN RARE-LIVER, Clichy, France.
- 53 * Contributed equally.
- 54
- 55

It is made available under a CC-BY-NC-ND 4.0 International license .

56 Abstract

57

58 Patient heterogeneity represents a significant challenge for both individual patient management and 59 clinical trial design, especially in the context of complex diseases. Most existing clinical classifications 60 are based on scores built to predict patients' outcomes. These classical methods may thus miss 61 features that contribute to heterogeneity without necessarily translating into prognostic 62 implications.

63 To address patient heterogeneity at hospital admission, we developed ClustALL, a computational 64 pipeline designed to handle common clinical data challenges such as mixed data types, missing 65 values, and collinearity. ClustALL also facilitates the unsupervised identification of multiple and robust stratifications. We applied ClustALL to a prospective European multicentre cohort of patients 66 with acutely decompensated cirrhosis (AD) (n=766), a highly heterogeneous disease. ClustALL 67 identified five robust stratifications for patients with AD, using only data at hospital admission. All 68 69 stratifications included markers of impaired liver function and number of organ dysfunction or 70 failure, and most included precipitating events. When focusing on one of these stratifications, 71 patients were categorized into three clusters characterized by typical clinical features but also having 72 a prognostic value. Re-assessment of patient stratification during follow-up delineated patients' 73 outcomes, with further improvement of the prognostic value of the stratification. We validated 74 these findings in an independent prospective multicentre cohort of patients from Latin America 75 (n=580). 76 In conclusion, this study developed ClustALL, a novel and robust stratification method capable of

77 addressing challenges tied to intricate clinical data and applicable to complex diseases. By applying

- 78 ClustALL to patients with AD, we identified three patient clusters, offering insights that could guide
- 79 future clinical trial design.
- 80
- 81

It is made available under a CC-BY-NC-ND 4.0 International license .

82 Introduction

Heterogeneity is a prevalent phenomenon observed in numerous diseases, including various types of 83 cancer (1), autoimmune conditions like multiple sclerosis (2), and diabetes (3)). This becomes 84 especially critical in diseases where environmental and lifestyle factors play a significant role. Acutely 85 86 decompensated cirrhosis, which refers to the rapid development of overt ascites, overt hepatic 87 encephalopathy, variceal haemorrhage, or any combination of these disorders, which often leads to 88 nonelective admission to the hospital of patients who were previously stable (4), exemplifies 89 significant inter-individual variability. It encompasses a range of causes of cirrhosis, comorbidities, precipitating events, clinical presentations, and outcomes (4). This clinical heterogeneity poses a 90 91 considerable challenge as it likely accounts for the diverse responses to treatment and outcomes 92 observed in these patients (5). Therefore, we reasoned that analysing a large population of patients 93 with acutely decompensated cirrhosis should allow us to develop stratification tools.

94

95 A major tool for the characterization of patient heterogeneity is the identification of patient 96 subtypes, also defined as patient stratification. Importantly, the World Health Organization has 97 acknowledged patient stratification as a valuable approach for enhancing population health 98 management and providing better-tailored services (6). In conceptual terms, patient stratification 99 can be described as the process of grouping or clustering patients based on specific characteristics or 100 patterns without relying on labelled data or information about future outcomes (7). Therefore, contrary to scores developed using classical statistical approaches based on the clinical course, 101 102 stratification can capture features explaining patients' heterogeneity independently of their 103 association with patient outcomes.

104

105 Numerous attempts have been made to identify subgroups within clinical datasets (7–9). However, 106 the lack of a universally applicable approach poses a significant challenge in the field of clustering 107 analysis. Although there have been advancements beyond the classical k-means and hierarchical 108 clustering methods, no general framework still allows the organization and classification of clustering 109 methodologies in the clinical setting (10). Instead, many ad-hoc applications have been developed for 110 specific scenarios, but their generalizability is often limited. While there is no global classification, 111 these applications can be grouped based on specific characteristics such as managing missing values, collinearity, or mixed data (9). For instance, when handling missing data, some methods exclude 112 113 samples from the analysis, potentially resulting in a loss of statistical power, while others rely on a 114 single imputation, overlooking the potential bias that can be introduced (11). Highly correlated 115 variables represent a challenge. Some methods exclude them, while others employ dimensionality 116 reduction techniques such as Principal Component (PC) reduction to capture underlying lower-117 dimensional data patterns (12,13). However, both decisions may affect the outcome of the 118 clustering, as sensitivity analyses are rarely conducted. Moreover, indiscriminate feature selection 119 can inadvertently remove informative features along with noisy ones, potentially biasing the results 120 (14). Furthermore, most clustering methodologies assume the existence of a single stratification, 121 disregarding the possibility of having none or multiple valid alternatives for subgrouping the 122 population (15). Interestingly, trace-based clustering methodologies have recently emerged to aid in 123 the interpretation and validation of the identified subgroups, often requiring domain knowledge and 124 expert input (16).

It is made available under a CC-BY-NC-ND 4.0 International license .

126 Additionally, the evaluation of clustering outcomes is an open problem that is based on the quality of the produced clusters. In the case of unsupervised clustering, where no preliminary classification 127 128 exists, evaluations are typically referenced against theoretical benchmarks. For instance, when 129 addressing the optimal number of clusters, various theoretical quality metrics are available such as 130 the clustering coefficient (17) or the silhouette index (18) among many others. Importantly, while 131 there is no universal methodology that excels across all scenarios for all data sets, as dictated by the 132 "no free lunch" theorem (19), there exist strategies that yield high-quality results (20–22). Another 133 essential measure-referred to as robustness-lacks a precise definition. Robustness, in general 134 terms, signifies the capacity of a system to withstand changes (23). In our context, we investigate 135 whether a clustering remains stable when subjected to perturbations. In this work, we considered 136 two types of perturbations: those derived from changes in the population and those arising from 137 changes in the algorithm's parameters. In the case of population-based perturbations, we quantify 138 how a given clustering is influenced by variations in the underlying population. Bootstrapping is one 139 approach to address this scenario (24). In the case of parameter-based perturbations, we assess the 140 impact of parameter adjustments in the clustering algorithm on the identified clustering (25). 141 Consider a scenario where a parameter "x" defines our clustering strategy. How different is the 142 resulting clustering when using "x=1" versus "x=1.1"? Here, robustness translates to clusterings that 143 maintain stability even when parameter values shift. For the reader's clarity, we will name the two 144 different robustness criteria: population-based robustness and parameter-based robustness. 145

146 Importantly, there is currently no methodology capable of addressing all the aforementioned 147 scenarios while ensuring both definitions of robustness. To address these challenges 148 comprehensively, we developed ClustALL, a novel framework that robustly identifies patient 149 subgroups by addressing all the previously mentioned challenges and limitations of existing 150 methodologies, and applied ClustALL -as a proof-of-concept- in two large prospective cohorts of 151 patients non-electively admitted to the hospital for acutely decompensated cirrhosis.

152

153 In this study, ClustALL was applied to a large prospective cohort of patients non-electively admitted 154 to the hospital for acutely decompensated cirrhosis. The resulting stratifications were thoroughly 155 characterized, aiming to identify any particular stratification of special interest in the clinical context 156 showing prognostic value. We then validated the reproducibility of this stratification using a separate 157 prospective cohort of patients. One further aim of the study was to demonstrate the usability of 158 stratification over the disease course, with prognostic value.

It is made available under a CC-BY-NC-ND 4.0 International license .

160 Results

161 ClustALL, a robust data-driven framework for patient stratification in complex162 diseases

163

164 We developed a specialized stratification framework, referred to as ClustALL, specifically designed to accurately identify all potential alternatives for stratifying a population using clinical multimodal data 165 166 at hospital admission as input. The ClustALL methodology consists of three main steps illustrated in 167 Figure 1 and detailed in the Methods section: (1) Data Complexity Reduction (depicted in the Green 168 Panel of Fig.1) aims to simplify the original dataset by mitigating the impact of redundant 169 information (highly correlated variables). As a result, we obtain a set of embeddings, each one 170 derived from different groupings of clinical variables. (2) Stratification Process (depicted in the 171 Purple Panel of **Fig.1**), where, for each embedding, multiple stratification analyses are performed 172 using different combinations of distance metrics and clustering methodologies. From each 173 combination, denoted as "embedding + distance metric + clustering method", a stratification is 174 derived. (3) Consensus-based Stratifications step (depicted in the Red Panel of Fig.1) aims to identify 175 robust stratifications that, in addition, exhibit minimal variation when combination parameters 176 ("embedding + distance metric + clustering method") are slightly modified. ClustALL performs a 177 population-based robustness analysis for each stratification using bootstrapping. This analysis 178 ensures that combinations associated with non-robust stratifications are excluded. The resulting 179 stratifications are then compared using the Jaccard distance. As a result, a heatmap is generated to 180 visually identify groups of representative stratifications (green squared lines). The selection of 181 representative stratifications enables the preservation of those stratifications that demonstrate 182 parameter-based robustness: consistency even when various parameters, like distance metrics or clustering methods, are altered. For each group of stratifications, the centroid is selected as the final 183 184 stratification (green squares). 185

186 Combining these three steps allows ClustALL to identify none, one, or multiple robust 187 stratifications in a given population of patients with complex diseases. Importantly, a specific 188 implementation of ClustALL is designed to effectively handle datasets with missing data effectively, 189 ensuring that incomplete information does not hinder the stratification process.

It is made available under a CC-BY-NC-ND 4.0 International license .

191 ClustALL uncovers stratification in a cohort of patients with acutely192 decompensated cirrhosis: a proof-of-concept

193 Study population.

The ClustALL approach was applied to a subset of individuals from the European PREDICT cohort (26), which included 766 patients with acute decompensation of cirrhosis and 74 clinical features collected at hospital admission, with less than 30% missing values. Complete information on patient characteristics and short-term outcomes, including acute-on-chronic liver failure (ACLF), liver transplant, and death, can be found in **Supplemental Table 1**.

200 ClustALL identified five different alternatives to stratify the population.

201 The ClustALL workflow was utilized to discover potential new sub-phenotypes of patients with acute 202 decompensation of cirrhosis within the PREDICT cohort upon hospital admission (Fig.2). To handle 203 missing values in the dataset, we employed the ClustALL framework, which incorporates imputations 204 using 1,000 iterations, as described in the Methods section. The Data Complexity Reduction Step 205 resulted in 72 embeddings (Fig.2.1). The Stratification Process generated 288 stratifications based on 206 the different combinations of "*embedding + distance metric + clustering method*" (Fig.2.2). Among 207 these, 144 population-based robust stratifications were identified through the Consensus-based 208 Stratifications step, resulting in five groups of parameter-based representative stratifications. The 209 centroid was selected for each group of stratifications, (Fig.2.3).

210

211 ClustALL provides better resolution than classical clustering tools

212 We conducted an analysis to assess the added value of ClustALL when compared with classical 213 clustering methodologies such as k-means or hierarchical clustering. Regarding the classical 214 methodologies, our findings revealed that when using correlation as a distance metric, 90% of 215 patients were consistently assigned to a single cluster, regardless of the number of clusters 216 considered; when Gower distance was utilized, the distribution of patients across clusters presented 217 a more balanced distribution (Table S2). Notably, the population-based robustness of the 218 stratifications generated by ClustALL was significantly higher (p-value <0.01) compared to the results 219 obtained using k-means and hierarchical clustering (Fig.S3). In summary, our observations 220 demonstrate that ClustALL significantly outperforms classical methodologies regarding population-221 based robustness.

222

223 Characterization of the five robust stratifications within the PREDICT population

224 After identifying the robust stratifications, we aimed to explore and characterize the distinct clusters 225 observed in each of the five alternative stratifications. These stratifications divided the patients into 226 two clusters, except for stratification 1, which had three clusters. We visually investigated the 227 separation by representing each stratification in a low-dimensional space using the corresponding 228 embeddings derived from the dendrogram depths (Fig.3A-E) and the complete dataset (Fig.S2). 229 Further exploration revealed that stratification 1 was a subdivision of stratification 2 (Fig.3F). We 230 then determined the minimal sets of variables (excluding the cirrhosis severity scores (Table S1 231 variables 44 to 48)) with the highest predictive performance in differentiating the clusters for each 232 stratification (Tables S3-S7) (27). The different classification approaches were described by 25 233 variables from a total of 74 (Table S1 variables 1 to 74), with 8 to 12 variables per stratification 234 (Fig.4A). Notably, all stratifications included: (i) serum bilirubin concentration (either as a continuous

It is made available under a CC-BY-NC-ND 4.0 International license .

235 variable or categorized under the term "liver dysfunction" (28)) (ii) International Normalized Ratio 236 (INR) (either as a continuous variable or categorized under the term "coagulation dysfunction" (28); 237 (iii) the number of organ dysfunction or failure. Precipitating events were present in all but one 238 stratification (stratification 3) either as a sum or individually (gastrointestinal bleeding, alcohol-239 related hepatitis, acute viral hepatitis). Diabetes mellitus was included in two stratifications. 240 Conversely, age, sex, BMI, cause of cirrhosis and lifestyle were present in no or one stratification. 241 Interestingly, stratification 1 and 2 shared almost the same minimal set of variables. Both 242 stratifications identified a group of patients with a severe phenotype attested by low serum sodium, 243 low serum albumin, high serum bilirubin, high INR, high C-Reactive Protein (CRP) and leucocytes, and 244 the number of precipitating events (Fig.4B). Hepatic encephalopathy was present in stratification 1 245 but not in 2 (29). A complete statistical characterization of the stratifications is provided in Tables S3 246 to S7. Considering the clinical implications of the features and the finer classification of the patients, 247 we identified stratification 1 as the most insightful for further exploration in patients with acute 248 decompensation of cirrhosis. Henceforth, in our discussions, we will refer to this specific stratification 249 as 'AD-strat'

250

251 AD-strat provides prognosis value

252 The AD-strat stratification is defined by three subgroups (clusters) of patients with acutely 253 decompensated cirrhosis revealing different clinical characteristics and disease progression. Cluster 254 1 included 306 patients (39.95%) who exhibited the most clinically critical scenario (Fig.5A, B and 255 Table S3). These individuals had the highest rates of organ dysfunction, clinical events, and 256 precipitating events (**Table S1**). They had a marked acute inflammatory profile (high white blood cell 257 count, and C-reactive protein level) poor liver function (low levels of albumin, and high levels of INR 258 and serum bilirubin) and more hepatocyte injury (higher levels of serum aspartate 259 aminotransferase). Conversely, Cluster 2 (n=118; 15.4%) and Cluster 3 (n=342; 44.6%) had a less 260 severe presentation. The main difference between Cluster 2 and 3 was hepatic encephalopathy, 261 found in 89% of the patients in Cluster 2 and almost no patients in Cluster 3 (Fig.5A, B and Table S2). 262 Importantly, a significant prognostic value of AD-strat was revealed by exploring the cumulative incidence of ACLF and death over 90-day follow-up (Fig.5C). Patients in Cluster 1 had poor short-263 264 term outcome, with a cumulative incidence of ACLF and death, both by 90 days of 24.1 and 21.5, 265 respectively. While Clusters 2 and 3 had similar risks of ACLF by 90 days (8.6% and 10.2 %, 266 respectively), the risk of death by 90 days was lower for Cluster 2 than Cluster 3 (4.3% vs 10.7%). 267

When we compared the clusters identified with ClustALL - exclusively using data obtained at admission - with the groups of patients based on their clinical course (26), we found a statistically significant association (Fisher test, p-value < 0.01) (see **Table S8**). We observed that 61% of patients with pre-ACLF were in Cluster 1 and 48% of patients with stable decompensated were in Cluster 3.

273

274

We assessed the validity of the *AD-strat* model in a large independent prospective multicentre cohort that included 580 patients with acute decompensation of cirrhosis from the Latin-American ACLARA study (30). Using as a reference the PREDICT *AD-strat* clusters, we labelled ACLARA patients using the k-nearest neighbours (kNN) classification algorithm (**Table S9**) (31). The classification model included the 12 predictive variables previously identified in the feature importance analysis

Reproducibility of the stratification model in an independent cohort

It is made available under a CC-BY-NC-ND 4.0 International license .

280 (Fig.3B Stratification 1). Importantly, the labelling was consistent and independent of the imputation 281 (Fig.6A), and the distribution of individuals by AD-strat clusters within ACLARA closely mirrored that 282 of the PREDICT cohort (Fig.6B). As expected, the clustering of the ACLARA cohort exhibited similar 283 clinical feature patterns to the PREDICT cohort (Fig.6C, Fig.3B Stratification 1). Furthermore, the 284 features describing the subgroups demonstrated statistical significance (Table S10). Finally, we 285 assessed the clinical relevance of the clustering in terms of prognosis, specifically examining the 286 short-term outcomes available in the ACLARA cohort 28 days after hospital admission. Similar to 287 results obtained in the PREDICT cohort, Cluster 1 displayed a bad prognosis for both ACLF and death, 288 while Cluster 3 showed a better prognosis (Fig.6D). In ACLARA, all patients from Cluster 2 were 289 afflicted by hepatic encephalopathy (Table S10) and showed a poor prognosis similar to that of 290 Cluster 1. Ethnicity was homogeneously distributed across clusters (Table S2). In particular, Native Americans represented 21% of Cluster 1, 15% of Cluster 2, and 14% of Cluster 3. Complete 291 292 information on patient characteristics and short-term outcomes is reported in Supplemental Table 293 9.

294

295

296

AD-strat as a marker for clinical management

Finally, we investigated the clinical value of the stratification during the follow-up visits of the PREDICT cohort. Based on the PREDICT study design (26), two follow-up visit plans were established depending on the reported disease severity (CLIF-C AD-score) at hospital admission (**Fig. 7A**). For patients with a CLIF-C AD-score \geq 50, the scheduled visits were performed at hospital admission and 1, 4, 8 and, 12 weeks after enrolment. For patients with a CLIF-C AD-score < 50, the scheduled visits were performed only at hospital admission and 1 and 12 weeks after enrolment.

303

304 Of the 766 patients included in the PREDICT study, 688 had at least one follow-up visit. For this 305 subset of patients with available data, we labelled each of them at each follow-up visit using the kNN 306 algorithm (Fig. 7B). This approach allowed an overview of the patient stratification over the entire 307 study duration and revealed the patient flow over time highlighting cluster transitions.

308

309 Consistent with the previous AD-strat characterization at hospital admission (Fig.5 and Table S3), we 310 identified more than 50% of patients with CLIF-C AD score \geq 50 (n=486) were classified as Cluster 1, 311 while patients with CLIF-C AD score < 50 (n=280) were predominantly classified as Cluster 3 (66.4%) 312 (Fig.7B). Changes in cluster proportions were observed during the patients' follow-up. Stratification 313 changes over time were more pronounced among patients with CLIF-C AD scores≥ 50 at hospital 314 admission, showing a progressive reduction of patients classified as Cluster 1 (55.8% at HA, 38.8% at 315 week 1, 39.2% at week 4, 25% at week 8, and 17.1% at week 12) and an increase of those classified 316 as Cluster 3 (32.1% at HA, 54.6% at week 1, 50.9% at week 4, 67.9% at week 8, and 74.3% at week 317 12). Additionally, there was a progressive increase in the proportion of patients classified as Cluster 318 3 for those patients with CLIF-C AD-score < 50 at hospital inclusion (66.4% at HA, 83.3% at week 1, 319 and 82.5% at week 12).

320

321 To assess the effectiveness of the *AD-strat* throughout disease progression, we determined its 322 prognostic value in two scenarios: 1) using the stratification at hospital admission, and 2) using the 323 stratification at the last visit reported before the occurrence of any adverse event (we considered 324 any visit between week 1 and 12) or at the end-of-study (EOS) (week 12 visit). A significant

It is made available under a CC-BY-NC-ND 4.0 International license .

325 difference was observed (p<0.001, Wilcoxon test) when comparing the time window between the

326 visit used in each scenario and the occurrence of adverse events (Fig. S5), indicating that in the

327 second scenario, we evaluated patients during a visit much closer to the event.

328

329 Ultimately, the cumulative incidence of ACLF and death as stratified at the last visit demonstrated a

330 more significant separation between clusters compared to patient stratification at hospital admission

331 (Fig.8). There was an increase in the incidence for those patients classified as Cluster 1 (18.46% and

332 $\,$ 18.45% at baseline and 28.16% and 26.8% at the last visit for ACLF and death, respectively).

333 Accordingly, the goodness-of-fit parameters indicated an improvement in risk prediction with the last

334 visit stratification, suggesting an enhanced predictive power as the event approached (Table S11).

335

It is made available under a CC-BY-NC-ND 4.0 International license .

337 Methods

338 ClustALL Framework

339 Given a set of patients affected by a complex disease with clinical data available, the goal of ClustALL

340 is to identify all the possible alternatives to stratify them that are robust and consistent, even when

341 different parameters or settings are used to generate the stratifications (distance metric, clustering

342 algorithm, and the number of imputations).

343

344 Input data

345 ClustALL accepts both binary and numerical clinical variables as input. Categorical features are 346 transformed using a one-hot encoder method. A minimum of two features is required, but including 347 more features would lead to more precise clustering. It is important to note that increasing the 348 number of features may also increase the computation time.

349

350 Step 1. Data Complexity Reduction

351 In this step, highly correlated features are replaced by a reduced set of variables that account for 352 their variability. To that end:

353 <u>Step 1.1. Dendrogram.</u> Hierarchical clustering is applied to the data, resulting in a 354 dendrogram where variables are grouped based on similarity (32). The depth of each branch 355 represents the distance between the groups of variables. All the possible depths of the dendrogram 356 are extracted, and the sets of variables beneath each depth are stored as *Depth*.

357 <u>Step 1.2. Preprocessing</u>. Principal Component Analysis (PCA) is computed for each set of 358 variables corresponding to each *Depth*, and the first three principal components are stored in a new 359 matrix (*Embedding*) (33). For sets that contain only one variable, the variable itself is stored to 360 generate the replacement matrix. This results in a complexity-reduced data set (*Embedding*) for each 361 considered *Depth*. A subset of depths can be considered when the number of variables is too large.

362

363 Step 2 Stratification Process

364 In this step, ClustALL calculates and pre-evaluates stratifications for each Embedding. For each 365 Embedding, the dissimilarity between patients' pairs is computed using correlation-based distance 366 and Gower dissimilarity metric, resulting in two distance matrices. Clustering algorithms are then 367 applied (34-36) depending on the distance used: k-means and hierarchical clustering for correlation 368 distance matrices, and k-medoids and hierarchical clustering for the Gower distance matrix. 369 Throughout all experiments, five different cluster numbers are evaluated $k \in \{2, 3, 4, 5, 6\}$. The 370 optimal number of clusters for each strategy is determined based on the consensus from three 371 different measures of clustering internal validation: the sum-of-squares based index or WB-ratio, the 372 Dunn index, and the average silhouette width (37,38). The objective is to group patients with 373 comparable data while ensuring that patients in separate clusters are as dissimilar as possible from 374 those in other clusters. As the output for this step, a stratification is derived for each combination 375 denoted as "embedding + distance metric + clustering method".

376

377 Step 3 Consensus-based stratifications

378 <u>Step 3.1. Population-based robustness.</u> A data-driven threshold is used to define 379 population-based robust subgroups or clusters. For each resulting stratification from the previous 380 step, cluster-wise stability is computed by bootstrapping the dataset 1,000 times and calculating the

It is made available under a CC-BY-NC-ND 4.0 International license .

381 Jaccard similarity index to the originally defined clusters (39). Stratifications with less than 85% 382 stability (Fig.S4) are excluded based on data distribution. The remaining stratifications are denoted 383 as Strat_{filt}.

384 Step 3.2. Jaccard distance is applied to compute distances between the population-based 385 robust stratifications. Then, to identify parameter-based robust clusters (where a minor modification 386 in parameter selection provides a similar result), ClustALL considers those combinations that are part 387 of a group of stratifications (green squares in Consensus-based stratifications step in Fig.1). Then, as 388 initial criteria, that can be modified by the user, centroids from each "combination group" are 389 selected as parameter-based robust stratifications (coloured green squares in Consensus-based 390 stratifications step in **Fig.1**). The outcome can be none, one, or multiple ways to stratify the 391 population robustly. In the current analysis, we considered parameter-based robust representatives: 392 centroids of a combination group that includes at least 5 population-based robust stratifications. 393

394 ClustALL enables input data with missing values

395 ClustALL can be adapted to work with missing data (Fig.S1). To that end, the ClustALL method is 396 modified as follows:

397 <u>Step 1 adaptation</u>. First, a dendrogram and its associated depths are computed considering the 398 original dataset with missing values. The original dataset is then imputed 1,000 times with the MICE 399 algorithm to ensure the results are not derived from a single imputation (40). For each *Depth* 400 *previously calculated* and each imputed dataset, the Data Complexity Reduction step is applied.

401 Step 2 adaptation. Step 2.1 is computed for each combination of depth, distance metric, clustering 402 algorithm and each Embedding derived from an imputed dataset. The selection of the optimal 403 number of clusters is based on the consensus from cluster internal validation and the mode of the 404 imputed datasets for each corresponding embedding. Afterward, a distance matrix (D_{mat}) between 405 individuals is obtained by computing how often two individuals are assigned to the same cluster in 406 each imputation (Fig.S1). Then, D_{mat} calculates a final stratification score using correlation-based 407 distance and h-clust. In our experience, limited optimization is required here because summarizing 408 the stratification over all imputations separately strengthens what is observed in each imputed 409 dataset. Extra care will be required only in cases where imputations may differ significantly. After 410 this modification, the method follows as previously described (Fig.S1).

411

412 Data source

413 The data utilized in this study were obtained from two independent multicentre studies: the 414 European PREDICT cohort and the Latin-American ACLARA cohort, conducted as part of the European 415 Project DECISION (26,41). Both cohorts collected various measures including clinical, 416 pharmacological, biomarker, and outcome data from patients with acute decompensation of 417 cirrhosis upon hospital admission and during follow-up visits. The follow-up period was 90 days for 418 the PREDICT cohort and 28 days for the ACLARA cohort. To be eligible for the present study, patients 419 were required to have acute decompensation of cirrhosis upon hospital admission, with available 420 information on short-term outcomes, drug intake, and available biological samples. Ultimately, 766 421 patients from the PREDICT cohort and 580 patients from the ACLARA cohort and 74 features 422 (continuous and categorical) were included in the analysis. The features included demographic 423 information, clinical and laboratory data, medical history, risk factors, and cirrhosis scores at hospital 424 admission, with missing values accounting for less than 30% (Table S1). To avoid bias from missing 425 data, imputation was performed with 1,000 iterations using the Multivariate Imputation by Chained

It is made available under a CC-BY-NC-ND 4.0 International license .

426 Equations (MICE) method (21).

	Age, sex, height ⁺ , weight ⁺ , BMI, ethnicity (Black or African
Demographics	American, Asian, White, other)
Cause of cirrhosis	Alcohol, viral, alcohol + viral, NASH, cryptogenic, other
Main reason for hospitalization	Ascites, hepatic encephalopathy, gastrointestinal bleeding, spontaneous bacterial peritonitis, other infection
Manifestations at admission	Clinical Events (ascites, hepatic encephalopathy, gastrointestinal bleeding, acute kidney injury, bacterial infection, acute alcoholic- steatohepatitis, acute viral hepatitis, hepatocellular carcinoma), number of clinical events (the sum of clinical events), number of precipitating events (the sum of precipitating events: proven bacterial infection, acute alcoholic-steatohepatitis, CLIF-C AD > 50), organ dysfunction (liver, renal, cerebral, coagulation, cardiac, respiratory), number of organ dysfunctions (the sum of organ dysfunctions), organ failure (liver, cerebral, coagulation, cardiac, respiratory), number of organ failures (the sum of organ failures)
Cirrhosis Severity Scores	Child-Pugh, CLIF-C AD, CLIF-C OF, MELD, MELDNA
Medical history	History of diabetes, history of hypertension, history of previous decompensations
Lifestyle	Alcohol, active alcohol consumption ⁺ , tobacco
Laboratory variables (measured in serum)	Alanine transaminase, aspartate aminotransferase, albumin, bilirubin (total), gamma-GT, C-reactive protein, sodium, potassium, glucose ⁺ , hemoglobin, hematocrit, creatinine, white blood cell count, lymphocytes, monocytes, neutrophils, INR (International Normalized Ratio), platelet, SpO2 (%), SpO2/FiO2 Ratio

Table 1. Complete list of input features. Patient characteristics included in the analysis: demographics,
 cause of cirrhosis, main reason for hospitalization, manifestations at admission, cirrhosis severity
 scores, medical history, lifestyle and laboratory variables. ⁺Variables not included in ACLARA cohort.

430

431 CLustALL comparison to different clustering methodologies

432 A comparison was conducted between the ClustALL framework and classical clustering algorithms. 433 Stratification was performed on 1,000 imputed datasets using classical k-means and hierarchical 434 methodologies with k values of 2 and 3, considering that ClustALL robust stratifications comprised 435 two or three patient subgroups. Bootstrapping was performed for the classical clusters to evaluate 436 cluster-wise stability (39). The resulting stability was compared to ClustALL stability through the 437 Kolmogorov–Smirnov test. Moreover, the clinical utility of the various stratifications was assessed by 438 examining the clinical insights obtained from the different clusters.

It is made available under a CC-BY-NC-ND 4.0 International license .

440 Statistical Methods

441 All analyses were performed in the R Computing Environment version 4.0.3 (42).

442

443 Descriptive statistics

444 Descriptive characteristics of the PREDICT and ACLARA study populations were reported as means 445 with standard deviations for continuous variables and proportions of patients for categorical 446 variables.

447 Feature Analysis

The identification of the minimal-size predictive signatures with maximal predictive power leading to each stratification was performed using the *fbed.reg* function with default hyperparameters from the 'MXM' R package (27).

451 Parametric Tests

452 Differences between clusters in the PREDICT and in the ACLARA cohorts were assessed using one-453 way ANOVA for continuous variables, while binary variables were tested with the chi-square test. 454 The association between the PREDICT clusters identified with ClustALL - exclusively using data 455 obtained at admission - with the groups of patients based on their clinical course (26), was tested 456 with the Fisher test.

457 Stratification model reproducibility

458 *AD-strat* model was validated in and in a separate cohort of patients with acute decompensation of 459 cirrhosis from the ACLARA cohort and in PREDICT follow-up time points. For this purpose, the kNN 460 model was trained on the PREDICT *AD-strat* cluster labels based on the signatures previously defined 461 as most predictive in the feature analysis. The K parameter was selected based on accuracy, the area 462 under the curve (AUC), error rate (ER), false positives (FP), and false negatives (FN) (**Table S7**). After 463 applying the KNN algorithm, the target data (ACLARA cohort and PREDICT follow-up) was labelled 464 based on the majority votes from the K nearest neighbours and imputed datasets.

465 Survival Analysis

466 Cumulative incidences of ACLF development and liver-related death were estimated using the 467 cumulative incidence function of the 'survival' R Package. Liver transplantation was considered a 468 competing event. A p-value lower than 0.05 with Benjamini and Hochberg (BH) adjustment was 469 considered statistically significant.

470

471 Longitudinal analysis and model evaluation

472 All PREDICT patients with ≥ 1 post-baseline assessment (n = 688) were included in longitudinal 473 outcomes analyses for a period of 90 days after hospital admission. Sankey diagrams were 474 generated to show the patients' transfers among the *AD-strat* clustering, liver transplant, ACLF 475 development, death and survival status. The predictive power of the stratification models at 476 different time points in the PREDICT cohort was evaluated using BIC, AIC, Concordance, and 477 Likelihood ratio goodness-of-fit parameters (41).

It is made available under a CC-BY-NC-ND 4.0 International license .

479 Discussion

480

481 Traditional patient classification methods based on outcome prediction scores may overlook 482 important heterogeneity factors. To address this issue, we developed ClustALL, a computational 483 pipeline that handles various clinical data challenges and identifies robust patient stratifications. We 484 applied ClustALL to a cohort of patients with acute decompensation of cirrhosis, identifying five 485 robust stratifications with prognostic value.

486

487 Optimal patient stratification is required to sustain the precision medicine revolution occurring in 488 the clinical setting (43). While significant progress has been made in classification problems, 489 particularly in domains like single-cell transcriptomic analysis (44,45), unsupervised clustering of 490 patients based on clinical information is still in the developmental stage (7,46). Notably, the existing 491 challenges in clinical stratification are often addressed using ad-hoc solutions that consider mixed 492 data types, missing values, or highly correlated variables. However, no comprehensive method 493 currently exists that addresses all these challenges. To overcome the aforementioned idiosyncrasies 494 in clinical data, we have developed a novel computational framework named ClustALL. Significantly, 495 beyond addressing existing challenges, ClustALL improves over other existing methodologies by 496 allowing the identification of more than one robust stratification within a given population. Clinical 497 data is complex and allows for multiple uses and "multiple interpretations" that may result in several 498 valid groupings (47). Indeed, the concept of "multiple interpretations" arises from how variables are 499 utilized in the clustering process and has been a subject of research in the early 21st century (48). 500 Another distinctive feature of ClustALL is the consistency of the resulting representative 501 stratifications even when limited modifications in the clustering parameter settings are applied. In 502 the context of biological data, such as gene expression data, this property has already been already 503 defined as the "propensity of a clustering algorithm to maintain output coherence over a range of 504 settings" (49). Interestingly, this definition has been applied in the study of exposome and 505 pregnancy-related mortality in the United States (50). In summary, we believe that ClustALL 506 represents one of the initial necessary steps towards incorporating two necessary features into 507 clinical stratification: parameter-based robustness and the identification of more than one 508 stratification.

509

510 To assess the effectiveness of ClustALL, we applied it as a proof-of-concept in a cohort of patients 511 with acutely decompensated cirrhosis considering data collected at hospital admission. Such an 512 attempt to apply stratification to patients with cirrhosis has never been conducted. The stratification 513 we set up differs from the scores developed and routinely used in patients with cirrhosis (e.g., MELD, 514 MELD-Na, Child-Pugh, CLIF-C-AD) both in terms of design and use. Indeed, all these scores were built 515 using a follow-up endpoint (usually death) in patients receiving therapies. These scores are helpful to 516 identify patients at high risk of poor outcomes, but they do not fully capture the heterogeneity of 517 the patients at admission for several reasons: (a) some features explaining patients heterogeneity 518 might not have an independent prognostic value, either because the prognostic information they 519 carry is contained in other variables, or because therapies administered to patients during their 520 follow-up blunt their impact; (b) a similar survival rate does not imply similar pathophysiological 521 mechanisms. For instance, in PREDICT, clusters 2 and 3 have a similar rate of ACLF, while they 522 strongly differ with regard to the prevalence of hepatic encephalopathy. The stratification presented 523 here is not intended to guide clinical bedside decisions or to replace a prognostic score but rather to

It is made available under a CC-BY-NC-ND 4.0 International license .

identify homogeneous patient populations at hospital admission. This stratification could base the development of future clinical trials including more homogeneous patient populations. In this regard, to make this stratification easily accessible to all, we developed an online calculator and application available at https://decision-for-liver.eu/for-scientists/clustall-web-application/. The purely data-driven approach and the development and independent validation of the stratifications in large prospective multicentre European and Latin American cohorts strengthen our results.

531 Through this analysis, as a first step, we identified five alternative stratifications for patients with 532 acute decompensation of cirrhosis. Interestingly, all stratifications included markers of impaired liver 533 function, namely serum bilirubin and INR, but also the number of organ dysfunction or failure, and 534 all but one included precipitating events. This emphasizes that these features are crucial when 535 designing a clinical trial including patients with acute decompensation of cirrhosis. On the contrary, 536 some features like age, sex, BMI, cause of cirrhosis and lifestyle were present in no or only one 537 stratification suggesting that these features are not key when designing a clinical trial. The 538 stratification we selected (AD-strat) provided a more granular resolution by allowing the 539 identification of three subgroups of patients. In this stratification, diabetes mellitus is taken into 540 account. While it is known that diabetes is an independent risk factor for cirrhosis decompensation 541 (51,52), the role of diabetes once acute decompensation has happened has been overlooked so far. 542 This place of diabetes is quite unique since causes of cirrhosis, comorbidities or lifestyle were not 543 part of the key features of AD-strat. Hepatic encephalopathy strongly impacted the categorization of 544 patients with acutely decompensated cirrhosis. Notably, 89% and 100% of the patients in Cluster 2 545 from the PREDICT and ACLARA cohorts, respectively, presented hepatic encephalopathy at the time 546 of hospital admission. This may explain the intermediate prognosis observed in patients within 547 Cluster 2, as hepatic encephalopathy is recognised by its fluctuating nature and potential 548 reversibility (53,54). The dynamic nature of hepatic encephalopathy may also explain why Cluster 2 549 was not a static group over time (55).

550

551 Furthermore, tracking patients over time using *AD-strat* labelling allowed for dynamic and improved 552 identification of patients at high risk of adverse events in the PREDICT cohort. These results highlight 553 the ability of the ClustALL not only to stratify patients using baseline characteristics but also that the 554 use of AD-strat labelling over time is able to improve this prediction.

555

Although our study showed promising results, it is important to acknowledge some limitations. Firstly, our stratification was based solely on routinely available clinical data at hospital admission, which may not provide a comprehensive view of patients' conditions. Future studies should extend our findings with biological data, ideally derived from multiomic analyses. Moreover, it is crucial to consider that the predictive power in the ACLARA cohort was only assessed at 28 days due to the study design.

562

563 In conclusion, this study introduces a novel unsupervised clustering framework, ClustALL, able to 564 overcome the limitations of previously available stratification methods. ClustALL is available as 565 OpenSource (<u>https://github.com/TranslationalBioinformaticsUnit/ClustALL_AD/</u>). When applied to 566 the setting of acute decompensation of cirrhosis, ClustALL enhanced our understanding of patients' 567 heterogeneity emphasizing the importance of liver function and the number of organ dysfunctions 568 or failures, precipitating events, and conversely the limited role of age, sex, BMI, cause of cirrhosis

It is made available under a CC-BY-NC-ND 4.0 International license .

- 569 and lifestyle at this stage of the liver disease. The selected stratification, *AD-strat*, might be a useful
- 570 tool to better design future clinical trials by including more homogeneous patient populations.

It is made available under a CC-BY-NC-ND 4.0 International license .

571 Data availability

572 Researchers who provide a methodology sound proposal can apply for the data, as far as the 573 proposal is in line with the research consented by the patients. These proposals should be requested 574 through <u>https://www.clifresearch.com/decision/Home.aspx</u>. Data requestors will need to sign a data 575 transfer agreement. The code to generate the ClustALL method is available on GitHub, at 576 <u>https://github.com/TranslationalBioinformaticsUnit/ClustALL AD/.</u>

577

578 Acknowledgements

579

580 This project has received funding from the European Union's Horizon 2020 research and innovation 581 program under grant agreement No 847949.

582

583 The study was supported by the European Foundation for the Study of Chronic Liver Failure (EF-Clif). 584 The EF-Clif is a nonprofit private organization. The EF-Clif receives unrestricted donations from Cellex 585 Foundation and Grifols. EF-Clif is partner, contributor and coordinator in several EU Horizon 2020 586 program projects. JT was appointed as visiting Professor in EF-Clif for the execution of the study by a 587 grant from Cellex Foundation. The funders had no influence on study design, data collection and 588 analysis, decision to publish or preparation of the manuscript.e fact that EF-CLIF.

589

Jonel Trebicka was supported by the German Research Foundation (DFG) project ID 403224013 – SFB 1382 (A09), by the German Federal Ministry of Education and Research (BMBF) for the DEEP-HCC project and by the Hessian Ministry of Higher Education, Research and the Arts (HMWK) for the ENABLE and ACLF-I cluster projects. The MICROB-PREDICT (project ID 825694), DECISION (project ID 847949), GALAXY (project ID 668031), LIVERHOPE (project ID 731875), and IHMCSA (project ID 964590) projects have received funding from the European Union's Horizon 2020 research and innovation program. The manuscript reflects only the authors' views, and the European Commission is not responsible for any use that may be made of the information it contains. The funders had no influence on study design, data collection and analysis, decision to publish, or preparation of the manuscript.

600

601 N.P.P was funded by a Ramón y Cajal fellow (RYC2021-032197-I) from the 602 MCIN/AEI/10.13039/501100011033 and European Union "NextGenerationEU"/PRTR and by a Juan 603 de la Cierva-formación fellow (FJC2019-042304-I) from the Spanish Ministry of Science and 604 Innovation (MCIN).

605

P-E.R.'s research laboratory is supported by the Foundation pour la Recherche Médicale (FRM
EQU202303016287), "Institut National de la Santé et de la Recherche Médicale" (ATIP AVENIR), the
"Agence Nationale pour la Recherche" (ANR-18-CE14-0006-01, RHU QUID-NASH, ANR-18-IDEX-0001,
ANR-22-CE14-0002) by « Émergence, Ville de Paris », by Fondation ARC and by the European Union's
Horizon 2020 research and innovation programme under grant agreement No 847949.

612 Bibliography

<i>c</i> 14	1	
614	1.	Almendro V, Kim HJ, Cheng YK, Gonen M, Itzkovitz S, Argani P, et al. Genetic and
615		phenotypic diversity in breast tumor metastases. Cancer Res. 2014 Mar
616	2	1;74(5):1338–48. Kotalnikova E. Kiani NA. Abad E. Martinaz Lanjagina EU. Andorra M. Zubizarrata
617	2.	Kotelnikova E, Kiani NA, Abad E, Martinez-Lapiscina EH, Andorra M, Zubizarreta
618		I, et al. Dynamics and heterogeneity of brain damage in multiple sclerosis. PLoS
619	2	Comput Biol. 2017 Oct 1;13(10).
620	3.	Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT. Disease progression
621		and treatment response in data-driven subgroups of type 2 diabetes compared with
622		models based on simple clinical features: an analysis using clinical trial data. Lancet
623		Diabetes Endocrinol. 2019 Jun 1;7(6):442–51.
624	4.	de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al.
625		Baveno VII – Renewing consensus in portal hypertension. Vol. 76, Journal of
626		Hepatology. Elsevier B.V.; 2022. p. 959–74.
627	5.	Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-Chronic
628		Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute
629		Decompensation of Cirrhosis. Gastroenterology. 2013 Jun;144(7):1426-1437.e9.
630	6.	Cerezo Cerezo J& ALC. Population stratification: a fundamental instrument used for
631		population health management in Spain: good practice brief World Health
632		Organization Regional Office for Europe
633		https://apps.who.int/iris/handle/10665/345586. 2018;
634	7.	Moral TT, Sanchez-Niubo A, Monistrol-Mula A, Gerardi C, Banzi R, Garcia P, et al.
635		Methods for Stratification and Validation Cohorts: A Scoping Review. Vol. 12,
636		Journal of Personalized Medicine. MDPI; 2022.
637	8.	Horne E, Tibble H, Sheikh A, Tsanas A. Challenges of clustering multimodal clinical
638		data: Review of applications in asthma subtyping. Vol. 8, JMIR Medical Informatics.
639		JMIR Publications Inc.; 2020.
640	9.	Wang H, Donoho D, Kuppler C, Loftus TJ, Jr UG, Copyright frai, et al. Phenotype
641		clustering in health care: A narrative review for clinicians.
642	10.	Saxena A, Prasad M, Gupta A, Bharill N, Patel OP, Tiwari A, et al. A review of
643		clustering techniques and developments. Neurocomputing. 2017 Dec 6;267:664-81.
644	11.	Cismondi F, Fialho AS, Vieira SM, Reti SR, Sousa JMC, Finkelstein SN. Missing
645		data in medical databases: Impute, delete or classify? Artif Intell Med. 2013
646		May;58(1):63–72.
647	12.	Rodríguez AH, Ruiz-Botella M, Martín-Loeches I, Jimenez Herrera M, Solé-Violan
648		J, Gómez J, et al. Deploying unsupervised clustering analysis to derive clinical
649		phenotypes and risk factors associated with mortality risk in 2022 critically ill
650		patients with COVID-19 in Spain. Crit Care. 2021 Dec 1;25(1).
651	13.	Curtis JR, Weinblatt M, Saag K, Bykerk VP, Furst DE, Fiore S, et al. Data-Driven
652		Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's
653		Rheumatoid Arthritis Sequential Study Registry. Arthritis Care Res (Hoboken). 2021
654		Apr 1;73(4):471–80.
655	14.	Pudjihartono N, Fadason T, Kempa-Liehr AW, O'Sullivan JM. A Review of Feature
656		Selection Methods for Machine Learning-Based Disease Risk Prediction. Frontiers in
657		Bioinformatics. 2022 Jun 27;2.
658	15.	Hennig C. What are the true clusters? Pattern Recognit Lett. 2015 Oct 15;64:53-62.
659	16.	Lopez-Martinez-Carrasco A, Juarez JM, Campos M, Canovas-Segura B. A
660		methodology based on Trace-based clustering for patient phenotyping. Knowl Based
661		Syst. 2021 Nov 28;232.
662	17.	Chalancon G, Kruse K, Babu MM. Clustering Coefficient. In: Encyclopedia of
663		Systems Biology. New York, NY: Springer New York; 2013. p. 422-4.

664	18.	Rousseeuw PJ. Silhouettes: A graphical aid to the interpretation and validation of
665		cluster analysis. J Comput Appl Math. 1987 Nov;20:53–65.
666	19.	Adam SP, Alexandropoulos SAN, Pardalos PM, Vrahatis MN. No Free Lunch
667		Theorem: A Review. In 2019. p. 57–82.
668	20.	Milligan GW, Cooper MC. An examination of procedures for determining the
669		number of clusters in a data set. Psychometrika. 1985 Jun;50(2):159–79.
670	21.	Steinley D, Brusco MJ. Choosing the number of clusters in K-means clustering.
671		Psychol Methods. 2011;16(3):285–97.
672	22.	Altman N, Krzywinski M. Clustering. Nat Methods. 2017 Jun 30;14(6):545–6.
673	23.	Kitano H. Towards a theory of biological robustness. Mol Syst Biol. 2007 Jan
674		18;3(1).
675	24.	Yu H, Chapman B, Di Florio A, Eischen E, Gotz D, Jacob M, et al. Bootstrapping
676		estimates of stability for clusters, observations and model selection. Comput Stat.
677		2019 Mar 28;34(1):349–72.
678	25.	Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering
679		algorithms. BMC Bioinformatics. 2019 Dec 24;20(S15):503.
680	26.	Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, et al. The
681		PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis
682		that have distinct pathophysiology. J Hepatol. 2020 Oct 1;73(4):842–54.
683	27.	Tsagris M, Tsamardinos I. Feature selection with the R package MXM. F1000Res.
684		2018 Jan 1;7:1505.
685	28.	Arroyo V, Moreau R, Jalan R. Acute-on-Chronic Liver Failure. New England Journal
686		of Medicine. 2020 May 28;382(22):2137–45.
687	29.	Stewart CA, Malinchoc M, Kim WR, Kamath PS. Hepatic encephalopathy as a
688		predictor of survival in patients with end-stage liver disease. Liver Transplantation.
689		2007 Oct;13(10):1366–71.
690	30.	Farias AQ, Vilalta AC, Zitelli PM, Pereira G, Goncalves LL, Torre A, et al. Genetic
691		Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America.
692		Gastroenterology [Internet]. 2023 May; Available from:
693		https://linkinghub.elsevier.com/retrieve/pii/S0016508523008065
694	31.	Deng Z, Zhu X, Cheng D, Zong M, Zhang S. Efficient kNN classification algorithm
695	011	for big data. Neurocomputing. 2016 Jun 26;195:143–8.
696	32.	Schonlau M. Visualizing non-hierarchical and hierarchical cluster analyses with
697	52.	clustergrams. Vol. 19, Computational Statistics. 2004.
698	33.	Ringnér M. What is principal component analysis? [Internet]. Vol. 26, NATURE
699	55.	BIOTECHNOLOGY. 2008. Available from:
700		http://www.nature.com/naturebiotechnology
701	34.	Hummel M, Edelmann D, Kopp-Schneider A. Clustering of samples and variables
702	54.	with mixed-type data. PLoS One. 2017 Nov 1;12(11).
702	35.	Zhang Z, Murtagh F, Poucke S Van, Lin S, Lan P. Hierarchical cluster analysis in
703	55.	clinical research with heterogeneous study population: Highlighting its visualization
704		with R. Ann Transl Med. 2017 Feb 1;5(4).
705	36.	Arora P, Deepali, Varshney S. Analysis of K-Means and K-Medoids Algorithm for
700	50.	Big Data. In: Physics Procedia. Elsevier B.V.; 2016. p. 507–12.
707	37.	
708 709	57.	Liu Y, Li Z, Xiong H, Gao X, Wu J. Understanding of internal clustering validation
		measures. In: Proceedings - IEEE International Conference on Data Mining, ICDM.
710	20	2010. p. 911–6.
711	38.	Zhao Q, Fränti P. WB-index: A sum-of-squares based index for cluster validity. Data
712		Knowl Eng. 2014;92:77–89.

 Van Buuren S, Groothuis-Oudshoom K. Journal of Statistical Software mice: Multivariate Imputation by Chained Equations in R [Internet]. Vol. 45, 2011. Available from: http://www.jstatsoft.org/ Farias AQ, Curto Vilalta A, Momoyo Zitelli P, Pereira G, Goncalves LL, Torre A, et al. Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirnbosis in Latin America. Gastroenterology. 2023 Sep:165(3):696–716. R Core Team, R: A language and environment for statistical . Vienna, Austria: R Foundation for Statistical Computing; 2021. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Vol. 14, Clinical and Translational Science. Blackwell Publishing Ltd; 2021. p. 86–93. Kiselev VY, Andrews TS, Hemberg M. Challenges in unsupervised clustering of single-cell RNA-seq data. Vol. 20, Nature Reviews Genetics. Nature Publishing Group; 2019. p. 273–82. Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 1196–208. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering: 2012. p. 1207–10. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United Stat	713 714	39.	Hennig C. Cluster-wise assessment of cluster stability. Comput Stat Data Anal. 2007 Sep 15;52(1):258–71.
 Multivariate Imputation by Chained Equations in R [Internet]. Vol. 45. 2011. Available from: http://www.jstatsoft.org/ Farias AQ. Curto Vilalta A, Momoyo Zitelli P, Pereira G, Goncalves LL, Torre A, et al. Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America. Gastroenterology. 2023 Sep.165(3):696–716. R Core Team. R: A language and environment for statistical . Vienna, Austria: R Foundation for Statistical Computing; 2021. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Vol. 14, Clinical and Translational Science. Blackwell Publishing Ltd; 2021. p. 86–93. Kiselev VY, Andrews TS, Hemberg M. Challenges in unsupervised clustering of single-cell RNA-seq data. Vol. 20, Nature Reviews Genetics. Nature Publishing Group; 2019. p. 273–82. Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell RNA-seq data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 1196–208. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. Lu Y, Phillips CA, Langston MA, Ar obustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. Harville EW, Grady SK, Langston MM, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high-dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1).		40.	
 Available from: http://www.jstatsoft.org/ 41. Farias AQ. Curto Vilalta A, Momoyo Zitelli P, Percira G, Goncalves LL, Torre A, et al. Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America. Gastroenterology. 2023 Sep;165(3):696–716. 42. R Core Team. R: A language and environment for statistical . Vienna, Austria: R Foundation for Statistical Computing; 2021. 43. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Vol. 14, Clinical and Translational Science. Blackwell Publishing Ltd; 2021. p. 86–93. 44. Kiselev VY, Andrews TS, Hemberg M. Challenges in unsupervised clustering of single-cell RNA-seq data. Vol. 20, Nature Reviews Genetics. Nature Publishing Group; 2019. p. 273–82. 45. Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 1196–208. 46. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. 47. Müller E, Günnemann S, Färber I, Scidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. 48. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. 49. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24:20. 41. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high-dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 42. Harville EW, Grady SK, Langston MJ, Juarez ZJ, Vilda D, Wallace ME. Th			
 41. Farias AQ, Curto Vilalta A, Momoyo Žitelli P, Pereira G, Goncalves LL, Torre A, et al. Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America. Gastroenterology. 2023 Sep:165(3):696–716. 22. R Core Team. R: A language and environment for statistical . Vienna, Austria: R Foundation for Statistical Computing; 2021. 23. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Vol. 14, Clinical and Translational Science. Blackwell Publishing Ltd; 2021. p. 86–93. 24. Kisselev VY, Andrews TS, Hemberg M. Challenges in unsupervised clustering of single-cell RNA-seq data. Vol. 20, Nature Reviews Genetics. Nature Publishing Group; 2019. p. 273–82. 24. Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 1196–208. 26. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. 27. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. 27. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. 201 Harville EW, Grady SK, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. 2016 Jul;36(7):936–48. 211 Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 214 Harville EW, Grady SK, Langston M, J			
 al. Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America. Gastroenterology. 2023 Sep;165(3):696–716. 42. R Core Team. R: A language and environment for statistical . Vienna, Austria: R Foundation for Statistical Computing; 2021. 43. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Vol. 14, Clinical and Translational Science. Blackwell Publishing Ld; 2021. p. 86–93. 44. Kiselev VY, Andrews TS, Hemberg M. Challenges in unsupervised clustering of single-cell RNA-seq data. Vol. 20, Nature Reviews Genetics. Nature Publishing Group; 2019. p. 273–82. 45. Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 1196–208. 46. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. 47. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering: 2012. p. 1207–10. 48. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. 49. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. 41. Jarville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International.		41.	1 5 6
 Latin America. Gastroenterology. 2023 Sep;165(3):696–716. R. Core Team. R: A language and environment for statistical . Vienna, Austria: R Foundation for Statistical Computing: 2021. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Vol. 14, Clinical and Translational Science. Blackwell Publishing Ltd; 2021. p. 86–93. Kiselev VY, Andrews TS, Hemberg M. Challenges in unsupervised clustering of single-cell RNA-seq data. Vol. 20, Nature Reviews Genetics. Nature Publishing Group; 2019. p. 273–82. Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 1196–208. Coombes CE, Liu X, Abrans ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabe			
 42. R Core Team. R: A language and environment for statistical . Vienna, Austria: R Foundation for Statistical Computing; 2021. 33. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Vol. 14, Clinical and Translational Science. Blackwell Publishing Ltd; 2021. p. 86–93. 44. Kiselev VY, Andrews TS, Hemberg M. Challenges in unsupervised clustering of single-cell RNA-seq data. Vol. 20, Nature Reviews Genetics. Nature Publishing Group; 2019. p. 273–82. 45. Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 1196–208. 46. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. 47. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2019. p. 257–84. 49. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. 50. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 52. Patermostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non Eselective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31;<			
 Foundation for Statistical Computing; 2021. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Vol. 14, Clinical and Translational Science. Blackwell Publishing Ltd; 2021. p. 86–93. Kiselev VY, Andrews TS, Hemberg M. Challenges in unsupervised clustering of single-cell RNA-seq data. Vol. 20, Nature Reviews Genetics. Nature Publishing Group; 2019. p. 273–82. Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 173–82. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1:22(1). Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non ⊡selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmaco		42.	
 43. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Vol. 14, Clinical and Translational Science. Blackwell Publishing Ltd; 2021. p. 86–93. 44. Kiselev VY, Andrews TS, Hemberg M. Challenges in unsupervised clustering of single-cell RNA-seq data. Vol. 20, Nature Reviews Genetics. Nature Publishing Group; 2019. p. 273–82. 45. Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 1196–208. 46. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. 47. Müller E, Ginnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. 48. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. 49. Lu Y, Philips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. 50. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the Unied States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 52. Patermostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non ⊡selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagn			
 Medicine, AI, and the Future of Personalized Health Care. Vol. 14, Clinical and Translational Science. Blackwell Publishing Ltd; 2021. p. 86–93. Kiselev VY, Andrews TS, Hemberg M. Challenges in unsupervised clustering of single-cell RNA-seq data. Vol. 20, Nature Reviews Genetics. Nature Publishing Group; 2019. p. 273–82. Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 1196–208. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24:20. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Jul 31; Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Ge;62(2):437–47. Higuera-de-la-Tijera F, Velarde-Ruiz		43.	1 6
 Translational Science. Blackwell Publishing Ltd; 2021. p. 86–93. Kiselev VY, Andrews TS, Hemberg M. Challenges in unsupervised clustering of single-cell RNA-seq data. Vol. 20, Nature Reviews Genetics. Nature Publishing Group; 2019. p. 273–82. Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 1196–208. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non □selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. Ferenci P. Hepatic encephalopathy.			
 44. Kiselev VY, Andrews TS, Hemberg M. Challenges in unsupervised clustering of single-cell RNA-seq data. Vol. 20, Nature Reviews Genetics. Nature Publishing Group; 2019. p. 273–82. 45. Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 1196–208. 46. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. 47. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. 48. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. 49. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. 41 50. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non □selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Get;62(2):437–47. 54. Ferenci P. Hepati			
 single-cell RNA-seq data. Vol. 20, Nature Reviews Genetics. Nature Publishing Group; 2019. p. 273–82. Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 1196–208. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. Feinci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. Fein		44.	
 Group; 2019. p. 273–82. 45. Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 1196–208. 46. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. 47. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. 48. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. 49. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24:20. 41 50. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al.			
 45. Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 1196–208. 46. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. 47. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. 48. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. 49. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. 50. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non □selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and co			
 RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University Press; 2019. p. 1196–208. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. Patermostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74.<		45.	
 Press; 2019. p. 1196–208. 46. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. 47. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. 48. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. 49. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. 49. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high-dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 52. Patemostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non □selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 			
 46. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. 47. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. 48. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. 49. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. 49. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non ⊟selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 			
 practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 		46.	
 47. Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions: grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. 48. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. 49. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. 50. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 			
 grouping objects in different views of the data. In: Proceedings - International Conference on Data Engineering. 2012. p. 1207–10. 48. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. 49. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. 50. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	734	47.	
 Conference on Data Engineering. 2012. p. 1207–10. 48. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. 49. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. 50. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non □selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 			
 48. Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84. 49. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. 741 50. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 744 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 747 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 751 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. 754 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 755 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 			
 Information Systems. Springer London; 2018. p. 257–84. 49. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20. 50. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high-dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non □ selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 		48.	
 algorithms. BMC Bioinformatics. 2019 Dec 24;20. 50. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non □ selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	738		· · · ·
 50. Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936-48. 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non □ selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437-47. 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138-47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155-74. 	739	49.	Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering
 health exposome and pregnancy-related mortality in the United States: a high- dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	740		algorithms. BMC Bioinformatics. 2019 Dec 24;20.
 dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1). 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non □ selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	741	50.	Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public
 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non □ selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	742		health exposome and pregnancy-related mortality in the United States: a high-
 patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48. 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non □ selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	743		dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1).
 2016 Jul;36(7):936–48. 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	744	51.	Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in
 Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes impairs the haemodynamic response to non selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	745		patients with cirrhosis: clinical implications and management. Liver International.
 impairs the haemodynamic response to non □ selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; S3. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	746		2016 Jul;36(7):936–48.
 cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023 Jul 31; 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	747	52.	Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes
 Jul 31; S3. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	748		impairs the haemodynamic response to non selective betablockers in compensated
 751 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 753 Feb;62(2):437–47. 754 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 755 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro 756 GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and 757 comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de 758 México (English Edition). 2023 Apr;88(2):155–74. 	749		cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023
 acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. Figuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	750		Jul 31;
 Feb;62(2):437–47. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. Figuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	751	53.	Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with
 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47. 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro 66. Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	752		
 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	753		Feb;62(2):437–47.
 GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de México (English Edition). 2023 Apr;88(2):155–74. 	754	54.	Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138-47.
 757 comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de 758 México (English Edition). 2023 Apr;88(2):155–74. 	755	55.	Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro
 757 comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de 758 México (English Edition). 2023 Apr;88(2):155–74. 			
	757		-
	758		México (English Edition). 2023 Apr;88(2):155–74.
137	759		
760	760		

It is made available under a CC-BY-NC-ND 4.0 International license .

761 Figure Legends

762

763 Figure 1. Schematic overview of the different steps of ClustALL approach (best viewed in colour). 764 ClustALL takes clinical variables as input. First, data complexity is reduced by grouping the features 765 into a dendrogram, assessing the resulting depths, and using Principal Component Analysis (PCA) 766 (green panel). The output is an embedding for each possible depth. Then, stratification is 767 computed considering the combination of different distance measures, clustering techniques, and 768 cluster numbers (K) (purple panel). In the final step, non-robust stratifications are filtered, and the 769 centroids derived from computing Jaccard (coloured green squares) similarity among the robust 770 stratifications (green squares) are considered the final representatives of the stratifications (red 771 panel).

772 Figure 2. Summary of the outputs from the different steps of the ClustALL framework when 773 applied to the PREDICT cohort (N=766). Input data comprised 74 clinical features with less than 774 30% missing values. The analysis utilized 1,000 imputed datasets. The Data Complexity Reduction 775 step (green) was applied to 72 depths of the 1,000 imputed datasets. The Stratification Process 776 step (purple) considered various clustering combinations resulting in 288 stratifications. After 777 bootstrapping, 144 robust stratifications remained. Finally, in the Consensus-based Stratification 778 step (red), five groups of robust stratifications (red squares) were identified, and the centroid was 779 selected from each group as the final stratifications (red coloured squares).

780 Figure 3. Principal Component projection of the ClustALL robust stratifications based on the 781 embedding associated with each stratification. (A-E). Low-dimension representation of the robust 782 stratifications after applying the ClustALL framework to the PREDICT cohort. For each one of the 5 783 robust stratifications identified by ClustALL, the Principal Component Analysis of the Embeddings 784 corresponding to the specific dendrogram depth associated with the stratification is shown. The x785 (Dim1) and y (Dim2) axes represent the first and second principal components respectively, which 786 are linear combinations of the original variables. (F). The overlap between the clusters in 787 stratifications 1 and 2 shows that stratification 1 is a subdivision of stratification 2.

788 Figure 4. Overview of the variables driving the ClustALL stratifications. (A). Heatmap with the 789 minimal set of variables required to describe the 5 different stratifications, accounting for 25 out of 790 74 input variables. (B). Heatmaps of the minimal set of patient characteristics per stratification. The 791 heatmap colour scale depends on the data type. In the case of binary variables, the value indicates 792 the percentage of patients with such binary characteristics, e.g., the presence of Diabetes Mellitus. 793 For continuous variables, the colour scale represents a scaled value from the highest cluster mean 794 (100.0) to the lowest cluster mean (0.0), e.g., Albumin and CRP. Abbreviations: ASH = Acute 795 Alcoholic-Steatohepatitis, AST = Aspartate aminotransferase, CL= Cluster, CRP = C-Reactive Protein, 796 HE = Hepatic encephalopathy, HCC = Hepatocellular Carcinoma, INR = International normalized 797 ratio, WBC = White blood cell counts.

798

Figure 5. Clinical overview of the AD-strat derived clusters in the PREDICT cohort. (A, B). Distribution of the highest predictive performance-related patient characteristics among AD-strat clusters; (A) categorical variables, (B) numerical variables. C) Cumulative incidence of ACLF (left) and death (right) according to the AD-strat clustering in PREDICT cohort considering 90 days after hospital admission, with the number of patients at risk per cluster (Transplantation counted as a competing risk to death). Abbreviations: AST = Aspartate aminotransferase, CRP = C- Reactive Protein, INR = International normalized ratio, WBC = White blood cell counts.


806 **Figure 6. Reproducibility of the AD-strat model in the ACLARA cohort.** (A) Distribution of the 807 labels in the ACLARA cohort after applying the kNN model 1,000 times. (B) Proportion of patients

It is made available under a CC-BY-NC-ND 4.0 International license .

808 distributed in the 3 clusters in the PREDICT and the ACLARA cohorts. (C) Heatmap of patient 809 characteristics per cluster in the ACLARA cohort. Bars on the right show the colour scale 810 representing the proportion with each binary characteristic, such as diabetes. Continuous 811 variables, such as bilirubin, represent a scaled value from the highest cluster mean (1.0) to the 812 lowest cluster mean (0.0). (D) Cumulative incidence of ACLF (up) and death (down) according to 813 the AD-strat clustering in ACLARA cohort considering 28 days after hospital admission, with the 814 number of patients at risk per cluster (Transplantation counted as a competing risk to death). 815 Abbreviations: AST = Aspartate aminotransferase, CRP = C- Reactive Protein, INR = International 816 normalized ratio, WBC = White blood cell counts.

817

818 Figure 7. Distribution and transition of the AD-strat derived clusters at different visits in the 819 PREDICT cohort. (A). Schematic representation of PREDICT study design. Two follow-up visit plans 820 were defined according to the reported disease severity (CLIF-C AD-score) at hospital admission 821 (red). The information about the occurrence of any adverse event (liver transplant, ACLF or death) 822 during the whole visit plan or the absence of events at the end of the study was tracked (blue). (B) 823 Sankey plots show the cluster label of each patient over the follow-up visits. The follow-up flows of 824 patients with CLIF-C AD >= 50 at hospital admission (up) and CLIF-C AD <50 at hospital admission 825 (down) are shown. The distribution of the patients assessed at each follow-up visit per cluster is 826 shown as frequency and proportion on the top of the Sankey representations. The accumulated 827 frequency and proportion of adverse events at each follow-up visit respecting the whole cohort 828 (for CLIF-C AD >=50, n=486; for CLIF-C AD < 50, n=280) are shown on the bottom of the Sankey 829 representations. Reported event/eos, shows the status of a patient at the "end of the study": 830 patients with a reported event or patients with no reported event.







Figure 3



Dim1 (12.6%)

_5


5

Dim1 (12.2%)

5

_5

Figure 4









Figure 5










Days after Hospital Admission


Figure 6


С















Figure 8 A

ò

Days after Hospital Admission

Risk of ACLF



ò

Days after Hospital Admission